EGFR Clinical Trials in Changsha, Hunan
8 recruitingChangsha, Hunan, China
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Lung Cancer (Non-Small Cell)Circulating Tumor DNAEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University210 enrolled1 locationNCT05598528
Recruiting
Phase 2
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc200 enrolled2 locationsNCT06706713
Recruiting
Phase 2
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+2 more
Hunan Province Tumor Hospital6,000 enrolled1 locationNCT04322890
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Non-Small Cell Lung Cancer With EGFR Mutation
Suzhou Genhouse Bio Co., Ltd.94 enrolled6 locationsNCT06306456
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728